Navigation Links
Solution to bacterial mystery promises new drugs

A 25-year quest to identify the first biochemical step that many disease-causing bacteria use to build their membranes has led to a discovery that holds promise for effective, new antibiotics against these bacteria, according to investigators at St. Jude Children's Research Hospital. The finding is significant because the biochemical step the antibiotic would block is not used by humans. Therefore, such a drug would not cause dangerous side effects.

A report on this finding appears in the September 1 issue of Molecular Cell.

The discovery also demonstrated that current textbooks use the wrong type of bacterium as a model to explain a critical biochemical step that most disease-causing bacteria use to make their membranes, according to Charles Rock, Ph.D., a member of the St. Jude Department of Infectious Diseases and senior author of the paper. As bacteria grow in size or divide, they must make additional membrane using a series of biochemical reactions. The first step in this process is the transfer of a fatty acid to a molecule called G3P. Bacteria then convert this molecule into a variety of other molecules called phospholipids, which are the building blocks of membranes.

"We identified a biochemical process that uses a previously unrecognized molecule as a raw material to make phospholipid," Rock said. "That discovery solved a mystery that has puzzled researchers for 25 years."

Scientists have used E. coli bacteria for many years as a model to understand how disease-causing bacteria make membrane phospholipids, but E. coli is an unsuitable model for most pathogens (disease-causing bacteria), according to Rock.

First, E. coli is a so-called gram-negative bacterium, while many of the pathogens researchers are interested in are gram-positive, Rock noted. Among those gram-positive organisms are Staphylococcus aureus, which causes skin infections and serious blood infections, and Streptococcus pneumoniae, which causes pneu
'"/>

Source:St. Jude Children's Research Hospital


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Solution to Pollution: New Bacteria Eats Toxic Waste
3. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
4. Solution to legionella
5. Anti-bacterial additive widespread in U.S. waterways
6. A bacterial genome reveals new targets to combat infectious disease
7. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
8. Scientists discover that host cell lipids facilitate bacterial movement
9. Protein prevents detrimental immune effects of bacterial sepsis
10. Researchers develop new method for facile identification of proteins in bacterial cells
11. A virus-like hitchhiker may trigger bacterial meningitis
Post Your Comments:
(Date:7/8/2008)...o stay fit, do their bit for the environment or av...eir health if they don,t choose the right bicycle....al surgeon Mr Vinod Nargund from St Bartholomew,s ...rnal BJU International . , He says that the pro...ection problems and soreness and skin irritations ...
(Date:7/8/2008)... . , Barcelona, Spain: Couples who need IVF... this will not lead to developmental problems in e...ual conference of the European Society of Human Re...Dr. Karin Middelburg, from the University Medical ... that the study, which looked at the quality of ge...
(Date:7/8/2008)... . , Barcelona, Spain: Children born after ...omb have higher birth weight than those born where...ed to the 24th annual conference of the European S...(Tuesday 8 July). The mothers had longer pregnanci...k of congenital malformations, said Dr. Anja Pinbo...
(Date:7/7/2008)...U.S. coral reef ecosystems are considered to be in...A analysis of the health of coral reefs under U.S....tate of Coral Reef Ecosystems of the United States...that the nation,s coral reef ecosystems, particula... face intense human-derived threats from coastal d...
Breaking Biology News(10 mins):Male cyclists risk sexual problems if they don’t choose the right bike 2IVF does not increase risk of developmental disorders in children 2Children born from frozen embryos weigh more and do better than those born after fresh transfer 2NOAA report states half of US coral reefs in 'poor' or 'fair' condition 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 1New insight into RA patient priorities and motivators for clinical trial involvement 21796 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 3Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 1Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 2Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 3Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 1Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 2Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 3Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 4Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 5Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 6Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 7Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 8Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 9Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 10Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 11Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 12Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 13Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 1Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 2Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 3Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 4Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 5
...at the Johns Hopkins Bloomberg School of Public He...r a variety of illnesses using genetically modifie...ctions. Oral adenovirus vaccines have long been pr...ieve their process for constructing a replicating ...nomical vaccines that provide longer-lasting disea...
...eport today in the journal Genome,Research that th...eviously intractable DNA sequence: a 554-kilobase-...man Y chromosome. This sequence,contains eight put...ex-associated height differences and gonadal tumor...f the few holes remaining in the,"finished" sequen...
...ave discovered that a protein that was originally ... resistance is actually a "missing enzyme" from th...cteria to scavenge iron. , The research appears as...he Journal of Biological Chemistry, an American So...al. , Mycobacterium tuberculosis, the causative a...
...pment in the analysis of cancer,has been announced... an,innovative method that enables the rapid advan... in cancer. According to the report,published in t...he,National Academy of Science (PNAS) in collabora...tute, Agilent has developed a specialised,microarr...
Other Biology News:Live Recombinant Adenovirus Vaccine Technique Explored 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Scientists find missing enzyme for tuberculosis iron scavenging pathway 2Breakthrough Microarray-based Technology for the Study of Cancer 2
(Date:7/8/2008)...IN FALLS, Ohio, July 8 /- Knowledge E...s announced today the release of The,2007-2008 Ort...ce for,objective, accurate, strategically oriented...summarizes the global orthopaedic market through,s...epair, Arthroscopy/Soft,Tissue Repair, Spinal Impl...
(Date:7/8/2008)...rgan-specific MRI Contrast Agent Approved in the U...n a Decade, WAYNE, N.J., July 8 /- B...diagnostic imaging, announced today that the U.S. ...VIST(R) (Gadoxetate Disodium),Injection, a gadolin...1-weighted magnetic resonance imaging (MRI) of the...
(Date:7/8/2008)...d and Management Focused on Near-Term Milestones a...Strategy, VANCOUVER and SAN DIEGO, July 8 /PRNews...FF), a clinical-stage developer of drugs for infec...pecial meeting of shareholders,for the purpose of ...(see,"Requisition of Shareholder Meeting"). Manage...
(Date:7/8/2008)... TechCFO, a leading provider of ou...es for technology and biotechnology companies, tod...rtner to its Boston office. Strickland is the late...ion, which opened in May of last year. , ... -- TechCFO, a leading provider of outsourced CFO...
Breaking Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8TechCFO Adds Gary Strickland as Partner in Boston Office 2
...eviously reported initiative to establish a citywi...communities of Waukesha, Wauwatosa and Brookfield ...a are already being pitched by Cellnet, the provid...Milwaukee,s network is being built by a different ...stablished so far, the city is essentially leasing...
...student Pengpeng Zhang successfully imaged a piece... centimeter-in thickness, she and her UW-Madison c...ed thinking, the feat should be impossible because...ct electricity. , ,"After she did it, we realized,... thinner than what people normally use," says UW-...
... Third Wave Technologies has settled with a Belg...ng patents. Third Wave will license hepatitis C vi...ndisclosed financial terms. , ,The two companies, ... Wave forged a deal under which Innogenetics was a... line of products in Europe. It was Third Wave,s f...
... First Business Bank plans to launch a remote di...ne County. , ,Companies that purchased the service...over the Internet to the bank, where they would be... that First Business Bank president and COO Michae...c markets. , ,The service would eliminate trips to...
Other Biology Technology:Study explains unexpected conductivity of nanoscale silicon 2Study explains unexpected conductivity of nanoscale silicon 3
UBN-1 (C-20)
Rabbit polyclonal to Neuron navigator 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH derived from within residues 1850 to the C-terminus of Mouse Neuron
Mouse HAI-1 Ectodomain MAb (Clone 199732)
pETDuet-1 is designed for the coexpression of two target genes.
Biology Products: